| Name | Title | Contact Details |
|---|
Health People is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.
Since 1875, AspenPointe has created help and hope for Colorado residents. We provide a broad range of services to meet individual and family needs in mental health, substance abuse, vocational skills training and employment, education, and restorative justice.
Shearwater Health, a global leader in Clinical Process Outsourcing (CPO®) has trained and augmented care teams with remote and onsite clinicians since 1973, reducing the strain on the healthcare system. With a global workforce of more than 4,000 expertly trained, clinical resources supported by innovative technology and Six Sigma process excellence, Shearwater Health offers both remote and onsite clinical expertise that can be deployed rapidly and securely. The organization recruits and trains nurses in skills such as utilization management, care management, patient care, and revenue cycle and supports their careers through education, including the US Nursing Licensure Exam.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.